Answers are grounded in this paper and cite their sources.
Scientific review demonstrates the structure and biological activity of recombinant erythropoietin, indicating its therapeutic potential for treating various anemias.
The successful cloning of the gene for human erythropoietin (EPO) (Jacobs et al. 1985; Lin et al. 1985) has yielded information on the genetic organization and protein structure of this hormone and has allowed assessment of its biological properties. Biological studies have clearly indicated the clinical potential for this hormone in treatment of various anemias, and initial clinical studies of recombinant-DNA-produced human EPO (r-hEPO)1 are now under way.
No takes yet. Share an insight, caveat, or question.
Browne et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: